INTRODUCTION {#s1}
============

Gastric cancer is one of the most common cancers with high mortality, ranking as the fifth most common and the third deadliest cancer in the world \[[@R1]\]. Decreasing trends in gastric cancer incidence and mortality have been reported in most industrialized countries, whereas it is still prevalent in developing countries, predominantly in China \[[@R2]\]. Despite remarkable progress achieved in multimodal therapy strategies, the survival of gastric cancer remains poor with overall 5-year survival rates hovering around 25% \[[@R3]\]. *Helicobacter pylori* (*H. pylori*) infection is a well-established risk factor for gastric cancer. However, some countries with a high *H. pylori* infection rate have disproportionately low gastric cancer incidence or mortality \[[@R4]-[@R6]\]. These observations suggested that rather than any single factor alone, the development of gastric cancer stem from a combination of multiple factors, such as *H. pylori* infection, nutritional deficiencies, a high salt or a low fiber diet, smoking, alcohol consumption, high body mass index \[[@R7], [@R8]\], and genetic predisposition \[[@R9]\].

DNA repair system is responsible for maintaining the stability and integrity of human genomic DNA \[[@R10]\], and DNA repair genes may serve as potential biomarkers for cancer predication and prognosis \[[@R11]\]. Nucleotide excision repair (NER), one of the highly evolutionarily conserved pathway, can monitor and repair a variety of DNA damages \[[@R12], [@R13]\]. Failure to repair DNA damages may lead to a number of human diseases including xeroderma pigmentosum (XP) \[[@R14]\]. X*eroderma pigmentosum group G* (*XPG*) gene is one of eight key genes \[*XPA* to *XPG*, and excision repair cross complementing group-1 (*ERCC1*)\] in the NER pathway \[[@R15]\]. XPG can recognize and cut DNA lesion on the 3′ side to ensure the proper repair of damaged DNA \[[@R16], [@R17]\]. XPG also serves as a nonenzymatic scaffolding for subsequent 5′ incision by the XPF/ERCC1 heterodimer during the NER process \[[@R18]\].

Thus far, a number of studies have reported the relationship between single nucleotide polymorphisms (SNPs) in the *XPG* gene and cancer risk, including lung cancer \[[@R19], [@R20]\], gastric cancer \[[@R21]-[@R24]\], esophageal squamous cell carcinoma \[[@R25]\], colorectal cancer \[[@R26]-[@R28]\], and neuroblastoma \[[@R29]\]. However, only a few papers with small sample sizes are available regarding the role of *XPG* gene SNPs in gastric cancer carcinogenesis, and conclusions remain conflicting \[[@R21]-[@R24]\]. Therefore, we performed this study to precisely determine the association between five potentially functional SNPs (rs2094258 C\>T, rs751402 C\>T, rs2296147 T\>C, rs1047768 T\>C and rs873601G\>A) in the *XPG* gene and gastric cancer susceptibility with a total of 1142 patients and 1173 cancer-free controls in a Southern Chinese population.

RESULTS {#s2}
=======

Population characteristics {#s2_1}
--------------------------

The final analysis consisted of 1142 cases and 1173 healthy controls ([Supplemental Table S1](#SD1){ref-type="supplementary-material"}). There were 65.59% and 67.26% men in cases and controls (*P=*0.393), respectively. However, regarding age, smoking status, drinking status, and pack-years, there existed significant difference (*P\<*0.0001) between the cases and controls. Thus, we further adjusted for these variables in the multivariate analyses. Of the gastric cancer patients, 240 (21.02%) cases were diagnosed with gastric cardia adenocarcinoma, while 902 (78.98%) cases were with non-gastric cardia adenocarcinoma. In term of stage, 140 (12.26%), 329 (28.81%), 456 (39.93%), and 217 (19.00%) cases were classified as TNM stage I, II, III, and IV, respectively, according to the 7^th^ Edition of the American Joint Committee on Cancer (AJCC) \[[@R30]\].

Associations between *XPG* gene polymorphisms and gastric cancer risk {#s2_2}
---------------------------------------------------------------------

The genotype frequencies of cases and controls for the five *XPG* SNPs and their associations with gastric cancer risk were summarized in Table [1](#T1){ref-type="table"}. Observed genotype frequency distributions of all SNPs among the control subjects were in agreement with Hardy-Weinberg equilibrium (HWE). In the single factor analysis, no significant associations were observed between any of all the five polymorphisms and gastric cancer risk before and after adjusting for age, gender, pack-years, smoking and drinking status. We then determined the risk genotypes for each SNP based on its association with gastric cancer susceptibility. If a genotype of a SNP was associated with increase gastric cancer risk \[odds ratio (OR)\>1\], the genotype was considered as a risk genotype, even if the association was not significant. When we combined the five polymorphisms, we observed that carriers of 3-4 risk genotypes had a significantly increased gastric cancer risk by 32%, when compared to carriers of 0-2 risk genotypes \[OR=1.32, 95% confidence interval (CI)=1.04-1.68, *P*=0.021\]. However, this association were weakened and became borderline significant (adjusted OR=1.29, 95% CI=0.99-1.69, *P=*0.062) after adjustment for age, gender, pack-years, smoking and drinking status.

###### Logistic regression analysis of associations between *XPG* and gastric cancer risk

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Genotypes        Cases\         Controls\          *P*[^a^](#tfn_001){ref-type="table-fn"}   Crude OR\              *P*         Adjusted OR\                                    *P*[^b^](#tfn_002){ref-type="table-fn"}
                   (n=1142)       (n=1173)                                                     (95% CI)                           (95% CI) [^b^](#tfn_002){ref-type="table-fn"}   
  ---------------- -------------- ------------------ ----------------------------------------- ---------------------- ----------- ----------------------------------------------- -----------------------------------------
  rs2094258                                                                                                                                                                       

  CC               499 (43.70)    527 (44.93)                                                  1.00                               1.00                                            

  CT               508 (44.48)    524 (44.67)                                                  1.02 (0.86-1.22)       0.789       0.99 (0.82-1.21)                                0.938

  TT               135 (11.82)    122 (10.40)                                                  1.17 (0.89-1.54)       0.265       1.17 (0.86-1.59)                                0.329

  Dominant         643 (56.30)    646 (55.07)        0.551                                     1.05 (0.89-1.24)       0.551       1.03 (0.85-1.24)                                0.794

  Additive model   0.534          1.06 (0.94-1.20)   0.338                                     1.05 (0.91-1.21)       0.488                                                       

  Recessive        1007 (88.18)   1051 (89.60)       0.277                                     1.16 (0.89-1.50)       0.277       1.17 (0.87-1.57)                                0.291

  rs751402                                                                                                                                                                        

  CC               426 (37.30)    433 (36.91)                                                  1.00                               1.00                                            

  CT               555 (48.60)    551 (46.97)                                                  1.02 (0.86-1.22)       0.796       1.09 (0.89-1.34)                                0.397

  TT               161 (14.10)    189 (16.11)                                                  0.87 (0.68-1.11)       0.258       0.87 (0.65-1.15)                                0.328

  Dominant         716 (62.70)    740 (63.09)        0.846                                     0.98 (0.83-1.16)       0.846       1.03 (0.85-1.25)                                0.740

  Additive model   0.387          0.95 (0.84-1.07)   0.401                                     0.97 (0.84-1.10)       0.606                                                       

  Recessive        981 (85.90)    984 (83.89)        0.176                                     0.86 (0.68-1.07)       0.177       0.83 (0.64-1.07)                                0.150

  rs2296147                                                                                                                                                                       

  TT               725 (63.49)    746(63.60)                                                   1.00                               1.00                                            

  CT               364 (31.87)    388 (33.08)                                                  0.97 (0.81-1.15)       0.694       0.98 (0.80-1.20)                                0.856

  CC               53 (4.64)      39 (3.32)                                                    1.40 (0.91-2.14)       0.123       1.28 (0.78-2.08)                                0.329

  Dominant         417 (36.51)    427 (36.40)        0.955                                     1.01 (0.85-1.19)       0.955       1.01 (0.83-1.22)                                0.927

  Additive model   0.249          1.05 (0.91-1.21)   0.544                                     1.04 (0.88-1.22)       0.672                                                       

  Recessive        1089 (95.36)   1134 (96.68)       0.105                                     1.42 (0.93-2.16)       0.107       1.28 (0.79-2.09)                                0.312

  rs1047768                                                                                                                                                                       

  TT               607 (53.15)    625 (53.28)                                                  1.00                               1.00                                            

  TC               445 (38.97)    461 (39.30)                                                  0.99 (0.84-1.18)       0.944       0.96 (0.79-1.17)                                0.706

  CC               90 (7.88)      87 (7.42)                                                    1.07 (0.78-1.46)       0.695       1.10 (0.77-1.58)                                0.591

  Dominant         535 (46.85)    548 (46.72)        0.950                                     1.01 (0.85-1.18)       0.950       0.98 (0.82-1.19)                                0.869

  Additive model   0.913          1.02 (0.89-1.15)   0.822                                     1.01 (0.87-1.17)       0.891                                                       

  Recessive        1052 (92.12)   1086 (92.58)       0.674                                     1.07 (0.79-1.45)       0.675       1.12 (0.79-1.59)                                0.521

  rs873601                                                                                                                                                                        

  GG               311 (27.23)    323 (27.54)                                                  1.00                               1.00                                            

  AG               557 (48.77)    598 (50.98)                                                  0.97 (0.80-1.17)       0.738       0.97 (0.78-1.21)                                0.796

  AA               274 (23.99)    252 (21.48)                                                  1.13 (0.90-1.42)       0.303       1.11 (0.85-1.44)                                0.448

  Dominant         831 (72.77)    850 (72.46)        0.870                                     1.02 (0.85-1.22)       0.870       1.01 (0.82-1.25)                                0.909

  Additive model   0.335          1.06 (0.94-1.19)   0.338                                     1.05 (0.92-1.20)       0.480                                                       

  Recessive        868 (76.01)    921 (78.52)        0.150                                     1.15 (0.95-1.40)       0.150       1.13 (0.91-1.41)                                0.286

  Risk genotypes                                                                                                                                                                  

  0                158 (13.84)    184 (15.69)        0.185                                     1.00                               1.00                                            

  1                613 (53.68)    638 (54.39)                                                  1.12 (0.88-1.42)       0.358       1.16 (0.88-1.52)                                0.295

  2                194 (16.99)    208 (17.73)                                                  1.09 (0.81-1.45)       0.575       1.13 (0.81-1.57)                                0.471

  3                176 (15.41)    142 (12.11)                                                  **1.44 (1.06-1.96)**   **0.019**   **1.45 (1.02-2.05)**                            **0.038**

  4                1 (0.09)       1 (0.09)                                                     1.17 (0.07-18.77)      0.915       2.61 (0.06-107.90)                              0.614

  0-2              965 (84.50)    1030 (87.81)                                                 1.00                               1.00                                            

  3-4              177 (15.50)    143 (12.19)        0.021                                     **1.32 (1.04-1.68)**   **0.021**   1.29 (0.99-1.69)                                0.062
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CI, confidence interval; OR, odds ratio.

Chi square test for genotype distributions between cases and controls.

Adjusted for age, gender, pack-years, smoking and drinking status in logistic regress models.

Stratification analysis {#s2_3}
-----------------------

In the stratified analysis by age, gender, smoking status, pack-year, drinking status, tumor sites and TNM stage, we further evaluated the effects of all the five SNPs and provided the results for rs751402 C\>T, rs873601 G\>A polymorphisms. The effects of combined risk genotypes on gastric cancer risk were also shown. We failed to find any significant association with gastric cancer risk for any studied variants among subgroups (Table [2](#T2){ref-type="table"}). When the risk genotypes were combined, the significant associations with 3-4 risk genotypes were observed in individuals older than 58 years (adjusted OR=1.90, 95% CI=1.06-3.41, *P*=0.030) and men (adjusted OR=1.50, 95% CI=1.07-2.11, *P*=0.019), when compared to 0-2 risk genotypes.

###### Stratification analysis for associations between the three *XPG* variant genotypes and gastric cancer risk in Chinese population

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables         rs751402\          Adjusted OR\   *P* [^a^](#tfn_003){ref-type="table-fn"}   rs873601\          Adjusted OR\   *P* [^a^](#tfn_003){ref-type="table-fn"}   Risk genotype\     Adjusted OR\   *P* [^a^](#tfn_003){ref-type="table-fn"}                                    
                    (cases/controls)   (95% CI)                                                  (cases/controls)   (95% CI)                                                  (case/control)     (95% CI)                                                                                   
  ----------------- ------------------ -------------- ------------------------------------------ ------------------ -------------- ------------------------------------------ ------------------ -------------- ------------------------------------------ --------- ---------------------- -----------
                    CC/CT              TT                                                                           GG/AG          AA                                                                           0-2                                        3-4                              

  Median age, yr                                                                                                                                                                                                                                                                            

  ≤58               508/850            90/166         0.89 (0.67-1.20)                           0.454              448/796        150/220                                    1.19 (0.93-1.53)   0.163          511/888                                    87/128    1.14 (0.84-1.55)       0.407

  \>58              473/134            71/23          0.82 (0.49-1.36)                           0.436              420/125        124/32                                     1.12 (0.72-1.75)   0.604          454/142                                    90/15     **1.90 (1.06-3.41)**   **0.030**

  Gender                                                                                                                                                                                                                                                                                    

  Males             637/655            112/134        0.84 (0.61-1.15)                           0.264              567/625        182/164                                    1.17 (0.89-1.55)   0.267          629/695                                    120/94    **1.50 (1.07-2.11)**   **0.019**

  Females           344/329            49/55          0.83 (0.53-1.31)                           0.431              301/296        92/88                                      1.07 (0.74-1.55)   0.708          336/335                                    57/49     0.98 (0.63-1.54)       0.940

  Smoking status                                                                                                                                                                                                                                                                            

  Never             633/559            102/103        0.77 (0.55-1.08)                           0.131              555/521        180/141                                    1.27 (0.94-1.68)   0.123          616/582                                    119/80    1.28 (0.90-1.82)       0.167

  Ever              348/425            59/86          0.89 (0.60-1.34)                           0.590              313/400        94/111                                     0.98 (0.68-1.40)   0.896          349/448                                    58/63     1.24 (0.80-1.92)       0.330

  Pack-year                                                                                                                                                                                                                                                                                 

  0                 633/559            102/103        0.77 (0.55-1.08)                           0.131              555/521        180/141                                    1.27 (0.94-1.68)   0.123          616/582                                    119/80    1.28 (0.90-1.82)       0.167

  ≤ 30              231/322            41/61          1.04 (0.63-1.71)                           0.891              211/295        61/88                                      0.93 (0.60-1.44)   0.750          232/331                                    40/52     1.04 (0.62-1.75)       0.894

  \> 30             117/103            18/25          0.70 (0.35-1.41)                           0.313              102/105        33/23                                      1.06 (0.56-2.03)   0.857          117/117                                    18/11     1.73 (0.73-4.09)       0.211

  Drinking status                                                                                                                                                                                                                                                                           

  Never             795/499            139/101        0.84 (0.62-1.13)                           0.237              708/470        226/130                                    1.16 (0.89-1.50)   0.280          790/522                                    144/78    1.17 (0.85-1.61)       0.326

  Ever              186/485            22/88          0.77 (0.44-1.35)                           0.357              160/451        48/122                                     1.11 (0.71-1.74)   0.659          175/508                                    33/65     1.46 (0.85-2.50)       0.169

  Tumor site                                                                                                                                                                                                                                                                                

  Cardia            205/984            35/189         0.88 (0.57-1.36)                           0.554              185/921        55/252                                     1.14 (0.78-1.66)   0.500          205/1030                                   35/143    1.39 (0.88-2.18)       0.156

  Non-cardia        776/984            126/189        0.81 (0.62-1.07)                           0.141              683/921        219/252                                    1.14 (0.90-1.43)   0.279          760/1030                                   142/143   1.31 (0.99-1.74)       0.059

  Duke stage                                                                                                                                                                                                                                                                                

  I/II              405/984            64/189         0.75 (0.53-1.06)                           0.106              360/921        109/252                                    1.13 (0.85-1.51)   0.407          397/1030                                   72/143    1.31 (0.92-1.86)       0.130

  III/IV            576/984            97/189         0.88 (0.65-1.18)                           0.397              508/921        165/252                                    1.16 (0.90-1.48)   0.261          568/1030                                   105/143   1.33 (0.98-1.81)       0.066
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CI, confidence interval; OR, odds ratio.

Obtained in logistic regression models with adjustment for age, gender, pack-years, smoking and drinking status with omitting the corresponding stratification factor.

Haplotype analysis {#s2_4}
------------------

The frequency of inferred haplotypes of *XPG* gene based on observed genotypes and their association with the risk of gastric cancer were shown in Table [3](#T3){ref-type="table"}. None of the haplotype was associated with gastric cancer risk significantly.

###### The frequency of inferred haplotypes of *XPG* gene based on observed genotypes and their association with the risk of gastric cancer

  Haplotypes [^a^](#tfn_004){ref-type="table-fn"}   Cases (n=2284)   Controls (n=2346)   Crude OR (95% CI)   *P*     Adjusted OR [^b^](#tfn_005){ref-type="table-fn"} (95% CI)   *P* [^b^](#tfn_005){ref-type="table-fn"}
  ------------------------------------------------- ---------------- ------------------- ------------------- ------- ----------------------------------------------------------- ------------------------------------------
  CTTTG                                             747 (32.71)      802 (34.19)         1.00                        1.00                                                        
  CTTTA                                             123 (5.39)       122 (5.20)          1.08 (0.83-1.42)    0.565   1.06 (0.78-1.44)                                            0.694
  CTTCG                                             4 (0.18)         5 (0.21)            0.86 (0.23-3.21)    0.821   0.64 (0.15-2.75)                                            0.547
  CTTCA                                             1 (0.04)         0                   /                   0.978   /                                                           0.981
  CTCTA                                             1 (0.04)         0                   /                   0.978   /                                                           0.980
  CCTTG                                             140 (6.13)       150 (6.39)          1.00 (0.78-1.29)    0.987   0.92 (0.70-1.23)                                            0.584
  CCTTA                                             67 (2.93)        80 (3.41)           0.90 (0.64-1.26)    0.540   0.80 (0.54-1.18)                                            0.253
  CCTCG                                             31 (1.36)        48 (2.05)           0.69 (0.44-1.10)    0.121   0.82 (0.49-1.40)                                            0.468
  CCTCA                                             73 (3.20)        66 (2.81)           1.19 (0.84-1.68)    0.332   1.17 (0.79-1.72)                                            0.443
  CCCTG                                             5 (0.22)         8 (0.34)            0.67 (0.22-2.06)    0.486   0.76 (0.21-2.76)                                            0.679
  CCCTA                                             2 (0.09)         2 (0.09)            1.07 (0.15-7.64)    0.943   1.58 (0.19-13.31)                                           0.674
  CCCCG                                             194 (8.49)       177 (7.54)          1.18 (0.94-1.48)    0.160   1.14 (0.88-1.47)                                            0.330
  CCCCA                                             118 (5.17)       118 (5.03)          1.07 (0.82-1.41)    0.611   1.16 (0.85-1.58)                                            0.358
  TTTTG                                             1 (0.04)         0                   /                   0.978   /                                                           0.976
  TCTTG                                             40 (1.75)        43 (1.83)           1.00 (0.64-1.55)    0.996   1.02 (0.62-1.68)                                            0.925
  TCTTA                                             528 (23.12)      498 (21.23)         1.14 (0.97-1.33)    0.108   1.13 (0.95-1.36)                                            0.169
  TCTCG                                             6 (0.26)         2 (0.09)            3.22 (0.65-16.01)   0.153   2.10 (0.40-11.05)                                           0.383
  TCTCA                                             53 (2.32)        64 (2.73)           0.89 (0.61-1.30)    0.542   0.87 (0.57-1.34)                                            0.538
  TCCTA                                             5 (0.22)         6 (0.26)            0.90 (0.27-2.94)    0.855   1.07 (0.30-3.83)                                            0.918
  TCCCG                                             11 (0.48)        9 (0.38)            1.31 (0.54-3.18)    0.548   1.41 (0.51-3.91)                                            0.504
  TCCCA                                             134 (5.87)       146 (6.22)          0.99 (0.76-1.27)    0.910   0.89 (0.66-1.18)                                            0.411

The haplotypes order were rs2094258, rs751402, rs2296147, rs1047768, and rs873601.

Obtained in logistic regression models with adjustment for age, gender, pack‐years, smoking and drinking status.

DISCUSSION {#s3}
==========

In the present study, we investigated the impact of five potentially functional *XPG* SNPs on gastric cancer risk in a Chinese Han population from South China. Our analysis indicated that none of these SNPs could individually influence the gastric cancer susceptibility. However, the individuals carrying 3-4 risk genotypes had a significantly increased gastric cancer risk, especially among those older than 58 years and men. To the best of our knowledge, this is the largest study to investigate the association of these five *XPG* polymorphisms with the gastric cancer risk by far.

XPG is an indispensable component of the NER pathway, which is responsible for the cleavage of DNA on the 3′ side of lesion and also recruit PCNA to the damage sites for the subsequent gap-filling DNA synthesis in mammals \[[@R31]\]. It is reported that XPG also participates in other cellular processes, such as transcription-coupled DNA repair and RNA polymerase II transcription \[[@R32], [@R33]\].

Recently, several studies have been carried out to explore the role of *XPG* polymorphisms in gastric cancer susceptibility; however, inconsistent results have been reported. We previously evaluated the association between *XPG* (rs2094258 C\>T, rs2296147 T\>C and rs873601 G\>A) and gastric cancer risk in an Eastern Chinese population with 1125 cases and 1196 controls. We found that the rs873601 G\>A polymorphism (located in the 3′ UTR) was significantly associated with an increased gastric cancer risk \[[@R22]\]. We also demonstrated that rs873601 A allele was significantly associated with reduced mRNA expression level of *XPG* gene. These three polymorphisms were also genotyped in 337 gastric cancer cases and 347 controls by Yang and coworkers \[[@R24]\]. Intriguingly, they found that the rs2296147 T\>C polymorphism was associated with a decreased gastric cancer risk, while the rs2094258 C\>T polymorphism was associated with an increased gastric cancer risk \[[@R24]\]. In a study by Duan et al. \[[@R21]\], composed of 400 gastric cancer cases and 400 healthy controls, both rs751402 C\>T and rs2296147 T\>C polymorphisms were shown to significantly increase gastric cancer risk. Recently, Chen et al. \[[@R23]\] explored the association of rs2094258 C\>T, rs751402 C\>T, rs2296147 T\>C and rs873601 G\>A polymorphisms with gastric cancer susceptibility in 692 cases and 771 healthy controls. However, only *XPG* rs873601 G\>A polymorphism appeared to be associated with the risk of gastric cancer. This controversy regarding the association might be partly due to ethnic and demographic differences, or insufficient statistical power caused by small sample size.

With this in mind, we conducted the current study with 1142 cases and 1173 controls. We found no significant association between variant genotypes of *XPG* polymorphisms and gastric cancer risk. However, the individuals carrying 3-4 risk genotypes were at significantly increased gastric cancer risk, especially for individuals older than 58 years and men. Overall, the negative results might be partially ascribed to the mild effect of each variant. In addition, the moderate sample size in this study might not be large enough to detect relatively weak association. Besides, complex interactions between environmental and genetic factors should be taken into account while measuring the true associations of *XPG* gene polymorphisms with gastric cancer.

Despite that this is the largest study to extensively analyze the association of five potentially functional *XPG* polymorphisms with gastric cancer in a Southern Chinese population, there still exists some limitations. First, frequency matching between cases and controls in this research were only performed on gender, but not on age, smoking and drinking status. We used multivariate logistic regression analysis to minimize the impact of these confounding factors, to some extent. Second, gastric cancer is a heterogeneous disease which might be influenced by other related factors such as *H. pylori* infection, diet, occupational exposure, and environmental factors. Since such information on participants was missing, the results should be explained with caution. Third, due to the hospital-based case-control design, our study was inevitably suffered from the selection bias. Moreover, the conclusions drawn from subjects residing in South China may not well represent other Chinese populations in the different regions. Fourth, only five potentially functional SNPs were included in this study. As a result, SNPs from the coding and the intron regions that may also be related to gastric cancer risk could be omitted. Finally, we only investigated the association between *XPG* gene polymorphisms and gastric cancer risk. Genetic variations in other genes (e.g. *KDM5A*, *DNAH7* \[[@R34]\], *PLCE1* \[[@R35]\], *PSCA* \[[@R36], [@R37]\], *PRKAA1* \[[@R38]\], *MUC1* \[[@R39]\]) reported to be specifically associated with gastric cancer initiation and progression were not investigated in the current study.

In conclusion, we found that none of the *XPG* rs2094258 C\>T, rs751402 C\>T, rs2296147 T\>C, rs1047768 T\>C and rs873601 G\>A polymorphisms was associated with gastric cancer susceptibility. However, cumulative effects of risk genotypes (3-4) on the risk of gastric cancer were observed. Further well-designed, prospective studies with large-scale multicenter investigations involving different ethnicities are required to verify our conclusions.

MATERIALS AND METHODS {#s4}
=====================

Study subjects {#s4_1}
--------------

The study protocol was approved by the institutional review board of Sun Yat-sen University Cancer Center. All participants of this study signed individual informed consent. This study consisted of 1142 patients and 1173 healthy controls as we describe previously \[[@R40]\]. All subjects were unrelated ethnic Han Chinese population from Southern China, mainly from Guangdong, Guangxi, and Hainan province. In general, the response rate of cases and controls was more than 85%.

SNP selection and genotyping {#s4_2}
----------------------------

Five potentially functional SNPs in the *XPG* gene were selected for this study as we described previously \[[@R28], [@R29]\]. Briefly, we searched the potentially functional candidate SNPs located in the 5′- flanking region, exon, 5′ UTR, and 3′ UTR, which might affect transcription activity and the microRNA binding site activity. As predicted by SNPinfo software (<http://snpinfo.niehs.nih.gov/snpinfo/snpfunc.htm>), five SNPs (rs2094258 C\>T, rs751402 C\>T, rs2296147 T\>C, rs1047768 T\>C and rs873601 G\>A) were potentially functional ([Supplemental Table 2](#SD1){ref-type="supplementary-material"}). All these SNPs have a minor allele frequency no less than 5% for Chinese Han subjects. There is no significant linkage disequilibrium (LD) (R^2^\<0.8) among these SNPs. DNA samples were genotyped by the Taqman real-time PCR method as we described previously \[[@R22], [@R41]\].

Statistical analysis {#s4_3}
--------------------

Goodness-of-fit *χ^2^* test was used to check whether genotype frequency distribution of each polymorphism in controls were in accordance with HWE. We compared the differences in demographic variables as well as genotype frequencies between cases and controls by using the two-sided *χ^2^* test. ORs and 95% CIs were used to estimate the effect of SNPs and haplotypes on gastric cancer risk. Adjusted ORs were calculated by unconditional multivariate logistic regression analysis, with adjustment for age, gender, pack-years, smoking and drinking status. We determined the risk genotypes for each SNP based on its association with gastric cancer susceptibility. If a genotype of a SNP was shown to increase gastric cancer risk (OR\>1), the genotype was regarded as a risk genotype. For example, as to the rs2094258 C\>T polymorphism, ORs of 1.02 (heterozygous model) and 1.17 (homozygous model) indicated that the T allele carriers (CT/TT) may have an increased risk when compared to those with CC genotypes (Table [1](#T1){ref-type="table"}). Thus, the CC wild-type genotype carriers was define as 0, while the CT or TT genotype carriers was defined as 1. We then divided subjects into two groups based the number of risk genotypes. Carriers of 3-4 risk genotypes represented those carrying 3-4 risk genotypes of the five SNPs, while 0-2 risk genotypes represented those carrying 0-2 risk genotypes. All statistical analyses were performed using SAS software (version 9.1; SAS Institute, Cary, NC). A *P* value of \<0.05 was considered as statistically significant.

SUPPLEMENTARY MATERIAL TABLES {#s5}
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